- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00611195
Remifentanil and Laryngeal Reflex Responses in Pediatric Patients With URI
Impact of Remifentanil Administration on Laryngeal Reflex Responses in Pediatric Patients With Upper Respiratory Anesthetized With Propofol
To describe respiratory and laryngeal responses to laryngeal stimulation during propofol anesthesia in children with upper airway infections. To determine whether the co-administration of remifentanil blunts these reflex responses. To test whether the co-administration of remifentanil results in a significant reduction of apnea with laryngospasm in these patients.
Hypotheses:
I: In children with a URI undergoing anesthesia with propofol, the incidence of apnea and laryngospasm after controlled stimulation is expected to occur 2.5 times more frequently than in children without URI (20 vs. 8%).
II: The incidence of apnea and laryngospasm is diminished after administration of remifentanil.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients undergoing anesthesia in the presence of an upper respiratory infection (URI) are very common in pediatric anesthesia practice. Although, clinical data confirm that children with URIs are at increased risk of perioperative complications, it has become standard practice not to postpone anesthesia in the presence of URI. While complications (such as cough, hypoxemia) can be anticipated, recognized, and treated, laryngospasm remains the most severe and dramatic complication. In clinical practice, patients who develop laryngospasm are greater than 2.5 times more likely to have an active upper respiratory infection; therefore, knowledge that allows for rational selections of anesthetic agents under this condition is highly warranted. Based on our results obtained in healthy children, the use of propofol appears to be most promising under these circumstances. For this reason, the laryngeal and respiratory reflex responses should be assessed in patients with URI anaesthetized with propofol.
Commonly held believes suggest, that the administration of opioids blunts airway reflexes, including laryngospasm. However, in a previous study of our group in children anesthetized with sevoflurane the administration of fentanyl effectively blunted all airway reflexes but laryngospasm. These results are in contrast to those obtained in adults anesthetized with propofol where fentanyl also effectively blunted laryngospasm.
In children the combined use of propofol and remifentanil has become more frequent, particularly because of its synergistic pharmacodynamic effect. Besides its use during surgical procedures, this regime is also being increasingly advocated for diagnostic procedures such as bronchoscopy and esophago-gastroduodenoscopy. These interventions include instrumentation of the airway in children that are at an increased risk of harmful effects of laryngeal reflex responses.
Despite their obvious clinical significance, reflexes that involve the function of the upper airway are only minimally understood and information on such reflexes is scarce in anesthetized humans. Nonetheless, a model was developed by analyzing respiratory variables and endoscopic images after stimulating the laryngeal mucosa with a small amount of distilled water. This model was successfully adapted to the pediatric setting by our group assessing the impact of propofol, sevoflurane, fentanyl and lidocaine administration on laryngeal reflex responses in preschool children.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland, 4058
- University Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ASA I + II
- elective intervention under general anesthesia
- acute upper respiratory tract infection
Exclusion Criteria:
- chronic respiratory tract infection
- fever >38,3° celsius
- productive cough
- neuromuscular disease
- malignant hyperthermia
- cardiac disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 1
Larynx assessment under stimulation
|
propofol 3micrgr/ml (TCI plasma concentration Kataria model) versus propofol 3micrgr/ml and remifentanil 0.05microgr/kg/min
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurence of laryngospasm (defined as complete closure of the vocal or false cords with apnea lasting >10sec) after laryngeal stimulation
Time Frame: 5min
|
5min
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas O Erb, MD, Universitiy children's hospital Basel
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Diseases
- Respiratory Tract Infections
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Hypnotics and Sedatives
- Remifentanil
- Propofol
Other Study ID Numbers
- UNIBAS:UKBB_ANE_LR5
- SNF3200B0-109322 (Other Identifier: SNF 3200B0-109322)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Upper Respiratory Infections
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH)WithdrawnUpper Respiratory Infections
-
University of UtahCompletedUpper Respiratory Infections
-
NovartisNovartis Consumer HealthCompleted
-
Stephen J. Teach, MD, MPHNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingAsthma in Children | Atopy | Viral Upper Respiratory InfectionUnited States
-
BioHealth Technologies Inc.CompletedUpper Respiratory InfectionsUnited States
-
Société des Produits Nestlé (SPN)Completed
-
Valenta Pharm JSCCompletedInfluenza | Viral Respiratory Infection | Acute Viral Upper Respiratory InfectionsRussian Federation
-
Materia Medica HoldingCompletedAcute Upper Respiratory InfectionsRussian Federation
-
Clinical Research Center Kiel GmbHEuropean Commission; BioActorCompletedCommon Cold | Upper Respiratory InfectionsGermany
Clinical Trials on propofol, remifentanil
-
University Medical Center GroningenCompletedAnesthesia | Hemodynamic Instability | Interaction | Disorder of Oxygen TransportNetherlands
-
University Medical Center GroningenCompleted
-
Hopital FochCompleted
-
Universidad de AntioquiaCompletedAnesthesia, General | Anesthesia, IntravenousColombia
-
Università degli Studi di FerraraCompletedTest the Differences Between Schinder's TCI Model and MCIItaly
-
Hospital General Universitario Gregorio MarañonMinistry of Health, SpainCompletedPatients Requiring Ambulatory Surgery Under General AnesthesiaSpain
-
Zhang HaopengCompleted
-
Alder Hey Children's NHS Foundation TrustUnknownStudy to Evaluate the Optimal Dose of Remifentanil During MRI of the Heart Under General AnaesthesiaHeart Diseases | Anaesthesia | Children | Magnetic Resonance ImagingUnited Kingdom
-
The Hospital for Sick ChildrenCompletedSpinal PunctureCanada
-
Yonsei UniversityCompletedOsteoarthritis | Short StatureKorea, Republic of